1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > Ophthalmic Therapeutic Drugs: Technologies and Global Markets

This BCC Research report identifies unmet clinical needs based on existing ophthalmic therapeutic drugs in retinal disease and diabetes related conditions as well exploring potential new markets in the treatment of orphan diseases, retinitis pigmentosa and uveitis. Includes forecasts through 2019.

Use this report to:
- Receive a detailed analysis of the recent advances in ophthalmic therapeutic medicine and its potential impact on the pharmaceutical industry.
- Examine market factors and to identify market potential through 2019.
- Learn about the new developments in ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.
- Identify unmet clinical needs based on existing ophthalmic therapeutic drugs.

Highlights
- The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.
- The global age-related macular degeneration (AMD) market is expected to grow to nearly $7.9 billion by 2019 from nearly $5.4 billion in 2014, a CAGR of 7.8% from 2014 to 2019.
- The global glaucoma therapeutic market generated revenue of $3.8 billion in 2014, and by 2019 this segment is expected to generate $6.4 billion, with a CAGR of 11.1% from 2014 to 2019.

Introduction & Scope

INTRODUCTION

STUDY GOALS AND OBJECTIVES
Around 285 million people are visually impaired worldwide; however, 80% of visual impairment can be prevented, detected or cured. This report provides a comprehensive analysis of the ophthalmic drug market by reviewing recent improvements in diagnosis and advances in product development, novel formulations and delivery devices, and clinical development of new drug classes to treat both the signs and symptoms of prevalent eye conditions. This report also discusses market trends and opportunities based on therapeutic areas and geographical regions. The report’s main focus is to identify unmet clinical needs based on existing ophthalmic therapeutic drugs in retinal disease and diabetes-related conditions as well exploring potential new markets in the treatment of orphan diseases, retinitis pigmentosa and uveitis.

REASONS FOR DOING THE REPORT
The ophthalmic market is dominated by five major companies, Alcon (Novartis), Allergan, Merck & Co, Pfizer and Roche, each vying for pole position in key therapeutic
fields such as age-related macular degeneration (AMD) and glaucoma. Around 60% of global revenues are generated in the U.S.; however, many of the leading agents are
either off-patent or face patent expiry in the next five years. This will allow innovative generic and formulation specialists to generate cost-effective mono and combination
therapies, and force existing companies to develop new classes of drugs to protect their franchises and address areas of unmet clinic needs. According to the

Pharmaceutical Research and Manufacturers of America (PhRMA), there are over 50 drugs in clinical development, including small molecule agents, biopharmaceuticals,
cell and gene-based therapies, many of which target the underlying cause of diseases and not just the symptoms. In 2014, the ophthalmic therapeutic drug market was
worth around $12.3 billion, and this is forecast to rise to over $19 billion by 2019, as the industry focuses on commercially viable targets of high unmet clinical need such as
orphan drugs diseases and the treatment of dry AMD.

SCOPE OF REPORT
This report on ophthalmic therapeutics drugs provides a brief description of the current status of the industry and recent developments. The report analyzes the market trends, and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, it will provide insights into new
developments into ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.

INTENDED AUDIENCE
This report provides a detailed analysis of the recent advances in ophthalmic therapeutic medicine and its potential impact on the pharmaceutical industry; it also
examines the market factors and identifies the market potential through 2019. The study is aimed at the pharmaceutical industry, biotechnology firms, generic
manufacturers and biosimilar manufacturers, as well as formulation specialists and device manufacturers interested in enhancing the development of new and existing
products in this field.

METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary sources were used in preparing this study. This analysis of ophthalmic therapeutic medicine breaks down the market by geography and
therapeutic field, and also analyzes current and potential opportunities for ophthalmic therapeutic drug development. It includes market values from 2013 and forecasts
market revenues through 2019. Primary research involved e-mail correspondence and telephone interviews for each market, category, segment and sub-segment across geographies. We wish to extend our thanks to those who took part in interviews for this report, especially the following,
who gave so generously of their time:
- Gregory D. Kunst, Global Marketing Director, Retina Pharmaceuticals, Alcon Inc., a Novartis Company.
- Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie Pharmaceuticals.

Table Of Contents

Ophthalmic Therapeutic Drugs: Technologies and Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE REPORT 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED REPORTS 3
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,
THROUGH 2019 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY
SEGMENT,2013-2019 ($ MILLIONS) 8
CHAPTER 3 RETINAL DISEASES: AGE-RELATED MACULAR DEGENERATION 10
RETINAL DISEASE 10
FIGURE 1 STRUCTURE OF THE EYE 10
AGE-RELATED MACULAR DEGENERATION (AMD) 11
FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS) 11
DISEASE SUBTYPES 12
Early AMD 12
Intermediate AMD 12
Late-Stage AMD 12
Dry AMD 12
Wet AMD 13
FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD 13
DIAGNOSIS RATE 14
CURRENT TREATMENT 14
TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD 15
CURRENT MARKET SIZE 15
TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019
($ MILLIONS) 15
TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 16
TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH
2019 ($ MILLIONS) 16
FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY,
2014 (%) 16
MARKET DRIVERS 17
AREAS OF UNMET CLINICAL NEED 18
TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT 18
NEW THERAPIES FOR WET AMD 18
CONBERCEPT (CHENGDU KANGHONG PHARMACEUTICAL GROUP) 19
LAMPALIZUMAB (GENENTECH) 19
BROLUCIZUMAB (ALCON) 20
FOVISTA + ANTI-VEGF COMBINATION (ALCON/OPHTHOTECH) 20
TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III 21
TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II 21
TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I 23
NEW TREATMENTS FOR DRY AMD 23
TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III 23
TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II 24
NEW THERAPIES 24
Emixustat Hydrochloride (Acucela/Otsuka) 24
FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS 25
GSK-933776 (GSK) 25
FUTURE MARKET SIZE 25
TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 25
TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH
2019 ($ MILLIONS) 27
SUMMARY 28
CHAPTER 4 GLAUCOMA 30
FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS) 30
DISEASE SUBTYPES 31
PRIMARY OPEN-ANGLE GLAUCOMA 31
PRIMARY ANGLE-CLOSURE GLAUCOMA 31
FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA 31
DIAGNOSIS RATE 32
CURRENT TREATMENT 33
TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS 33
MONOTHERAPY 34
TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY 34
FIXED DOSE COMBINATIONS 35
TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE
COMBINATIONS 35
Prescription Patterns 35
FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%) 35
FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%) 36
FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%) 37
CURRENT MARKET SIZE 38
TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019
($ MILLIONS) 38
TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 40
FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY
DRUG CLASS, 2014 (%) 41
TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY,
THROUGH 2019 ($ MILLIONS) 42
FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY
COMPANY, 2014 (%) 42
MARKET DRIVERS 43
AREAS OF UNMET CLINICAL NEED 43
TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT 44
NEW DELIVERY APPROACHES AND FORMULATIONS 44
TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III 45
TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II 46
TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I 47
NEW THERAPIES 47
RHO KINASE (ROCK) INHIBITORS 48
GLANATEC (KOWA) 48
RHOPRESSA AND ROCLATAN (AERIE PHARMACEUTICALS) 48
FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS'
RHOPRESSA 48
TABLE 23 ROCK INHIBITORS IN DEVELOPMENT 50
GENE SILENCING AGENTS 50
TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT 50
BAMOSIRAN (SYLENTIS SA) 50
IST-0036 (ISARNA THERAPEUTICS GMBH) 51
QPI-1007 (QUARK PHARMACEUTICALS) 51
EARLY-STAGE DRUG DEVELOPMENT 52
ANTI-AMYLOID BETA AGENTS 52
CANNABINOIDS 52
TRANSIENT RECEPTOR POTENTIAL VANILLOID ISOFORM 4 (TRPV4) 52
FUTURE MARKET SIZE 53
TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 53
TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS,
THROUGH 2019 ($ MILLIONS) 55
SUMMARY 55
CHAPTER 5 DRY EYE SYNDROME 58
FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS) 58
DIAGNOSIS RATE 59
CURRENT TREATMENT 59
TABLE 27 PRODUCTS APPROVED TO TREAT DES 60
CURRENT MARKET SIZE 60
TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 ($
MILLIONS) 61
TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 62
FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG
CLASS, 2014 (%) 62
TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH
2019 ($ MILLIONS) 64
FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY,
2014 (%) 64
MARKET DRIVERS 65
AREAS OF UNMET CLINICAL NEED 65
TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT 66
NEW THERAPIES 66
CYCLOKAT/IKERVIS (SANTEN PHARMACEUTICAL) 66
LIFITEGRAST (SHIRE) 66
REFRESH (ACTAVIS) 67
EBI-005 (ELEVEN BIOTHERAPEUTICS) 67
EGP-435 (EYEGATE PHARMA/VALEANT PHARMACEUTICALS) 67
MIM-D3 (MIMETOGEN) 67
TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III 68
TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II 68
NEW FORMULATIONS 69
EARLY-STAGE DRUG DEVELOPMENT 69
FUTURE MARKET SIZE 69
TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 70
TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH
2019 ($ MILLIONS) 71
SUMMARY 71
CHAPTER 6 UVEITIS 73
FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS) 73
DIAGNOSIS RATE 74
CURRENT TREATMENT 75
TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS 75
CURRENT MARKET SIZE 75
TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 ($
MILLIONS) 76
TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 76
FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG
CLASS, 2014 (%) 76
TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY,
THROUGH 2019 ($ MILLIONS) 78
FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY
COMPANY, 2014 (%) 78
MARKET DRIVERS 79
AREAS OF UNMET CLINICAL NEED 79
TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT 79
NEW THERAPIES 80
GEVOKIZUMAB (XOMA) 80
SIROLIMUS (SANTEN PHARMACEUTICAL) 80
TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III 81
TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II 81
TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I 82
NEW FORMULATIONS 82
EGP-437 (EYEGATE PHARMA/ VALENAT PHARMACUETICALS) 82
EARLY-STAGE DRUG DEVELOPMENT 83
FUTURE MARKET SIZE 83
TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 83
TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS,
THROUGH 2019 ($ MILLIONS) 85
SUMMARY 85
CHAPTER 7 RECENT MARKET ACTIVITY 87
ALLIANCES AND LICENSING DEALS 87
FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014
(NO. OF DEALS) 87
FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY,
2007-2014 (NO. OF DEALS) 87
TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY
2015 ($ MILLIONS) 89
TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 ($
MILLIONS) 90
TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014
($ MILLIONS) 91
ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY 91
FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC
CATEGORY, 2007-2014 (NO. OF DEALS) 91
TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 ($
MILLIONS) 93
TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE,
2007-2014 ($ MILLIONS) 95
TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE,
2007-2014 ($ MILLIONS) 96
MERGERS AND ACQUISITIONS 96
FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014
(NUMBER) 96
TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE,
2007- JULY 2015 ($ MILLIONS) 98
CHAPTER 8 COMPANY PROFILES 101
LEADING PHARMACEUTICALS COMPANIES 101
ACTAVIS (FORMERLY ALLERGAN) 101
ALCON 101
F. HOFFMANN-LA ROCHE 102
MERCK and CO. 103
SHIRE PLC 104
SUMITOMO DAINIPPON PHARMA 104
VALEANT PHARMACEUTICALS 105
LEADING SPECIALIST PHARMA COMPANIES 106
ACUCELA 106
AERIE PHARMACEUTICALS 106
INOTEK PHARMACEUTICALS 107
LUX BIOSCIENCES 107
MOLECULAR PARTNERS AG 108
OPTHERION PHARMACEUTICALS 108
PSIVIDA CORPORATION 109
REGENERON PHARMACEUTICALS 109
RESOLVYX PHARMACEUTICALS 110
SANTEN PHARMACEUTICAL CO. LTD 110
SYLENTIS S.A. 111
LEADING GENERIC AND BIOSIMILAR MANUFACTURER 111
AKORN INC. 111
CHAPTER 9 APPENDIX I: ACRONYMS 113
ACRONYMS 113
CHAPTER 10 APPENDIX II: REFERENCES 115
AMD REFERENCES 115
GLAUCOMA REFERENCES 116
DRY EYE SYNDROME REFERENCES 119
UVEITIS REFERENCES 120
WEBSITES 120
WEBLINKS 121

LIST OF TABLES
TABLE HEADING PAGE NO.
SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,
THROUGH 2019 ($ MILLIONS) 7
TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD 15
TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019
($ MILLIONS) 15
TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH
2019 ($ MILLIONS) 16
TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH
2019 ($ MILLIONS) 16
TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT 18
TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE III 21
TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II 21
TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I 23
TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III 23
TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II 24
TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS) 25
TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH
2019 ($ MILLIONS) 27
TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS 33
TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY 34
TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE
COMBINATIONS 35
TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 ($
MILLIONS) 38
TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 40
TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY,
THROUGH 2019 ($ MILLIONS) 42
TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT 44
TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III 45
TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II 46
TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I 47
TABLE 23 ROCK INHIBITORS IN DEVELOPMENT 50
TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT 50
TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 53
TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS,
THROUGH 2019 ($ MILLIONS) 55
TABLE 27 PRODUCTS APPROVED TO TREAT DES 60
TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 ($
MILLIONS) 61
TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH
2019 ($ MILLIONS) 62
TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH
2019 ($ MILLIONS) 64
TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT 66
TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III 68
TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II 68
TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS) 70
TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH
2019 ($ MILLIONS) 71
TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS 75
TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 ($
MILLIONS) 76
TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS) 76
TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY,
THROUGH 2019 ($ MILLIONS) 78
TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT 79
TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III 81
TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II 81
TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I 82
TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($
MILLIONS) 83
TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS,
THROUGH 2019 ($ MILLIONS) 85
TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY
2015 ($ MILLIONS) 89
TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 ($
MILLIONS) 90
TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 ($
MILLIONS) 91
TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 ($
MILLIONS) 93
TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE,
2007-2014 ($ MILLIONS) 95
TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE,
2007-2014 ($ MILLIONS) 96
TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE,
2007- JULY 2015 ($ MILLIONS) 98

LIST OF FIGURES
FIGURE TITLE PAGE NO.
SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY
SEGMENT,2013-2019 ($ MILLIONS) 8
FIGURE 1 STRUCTURE OF THE EYE 10
FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS) 11
FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD 13
FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY,
2014 (%) 16
FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS 25
FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS) 30
FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA 31
FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%) 35
FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%) 36
FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%) 37
FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG
CLASS, 2014 (%) 41
FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY
COMPANY, 2014 (%) 42
FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS'
RHOPRESSA 48
FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS) 58
FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS,
2014 (%) 62
FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY,
2014 (%) 64
FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS) 73
FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG
CLASS, 2014 (%) 76
FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY,
2014 (%) 78
FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO.
OF DEALS) 87
FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY,
2007-2014 (NO. OF DEALS) 87
FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC
CATEGORY, 2007-2014 (NO. OF DEALS) 91
FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 2007-2014
(NUMBER) 96

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Insulin Markets in the World to 2019 - Market Size, Development, and Forecasts

Insulin Markets in the World to 2019 - Market Size, Development, and Forecasts

  • $ 23 395
  • Industry report
  • August 2015
  • by Global Research & Data Services Oy

The expansion of the global insulin industry is forecast to reach 9.0% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 11.2%. Currently, dosage insulin ...

2015-2019 Global Microbiology Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

2015-2019 Global Microbiology Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

  • $ 21 100
  • Industry report
  • July 2015
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2015-2019 Global Microbiology Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent ...

Future Horizons and Growth Strategies in the Global Virology and Bacteriology Testing Market 2015: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Virology and Bacteriology Testing Market 2015: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • June 2015
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “Future Horizons and Growth Strategies in the Global Virology and Bacteriology Testing Market 2015” is ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK

  • September 2015
    13 pages
  • Mental Illness  

  • United Kingdom  

View report >

Anti-infective Industry in the UK

  • September 2015
    52 pages
  • Anti-infective  

    Antibiotic  

    Respiratory Dis...  

  • United Kingdom  

View report >

Pathology Description in the US

  • August 2015
    10 pages
  • Mental Health  

    Hospital  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.